Literature DB >> 22532567

Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.

Siu Chiu Chan1, Yingming Li, Scott M Dehm.   

Abstract

Synthesis of truncated androgen receptor (AR) splice variants has emerged as an important mechanism of prostate cancer (PCa) resistance to AR-targeted therapy and progression to a lethal castration-resistant phenotype. However, the precise role of these factors at this stage of the disease is not clear due to loss of multiple COOH-terminal AR protein domains, including the canonical nuclear localization signal (NLS) in the AR hinge region. Despite loss of this NLS, we show that diverse truncated AR variant species have a basal level of nuclear localization sufficient for ligand-independent transcriptional activity. Whereas full-length AR requires Hsp90 and importin-β for active nuclear translocation, basal nuclear localization of truncated AR variants is independent of these classical signals. For a subset of truncated AR variants, this basal level of nuclear import can be augmented by unique COOH-terminal sequences that reconstitute classical AR NLS activity. However, this property is separable from ligand-independent transcriptional activity. Therefore, the AR splice variant core consisting of the AR NH(2)-terminal domain and DNA binding domain is sufficient for nuclear localization and androgen-independent transcriptional activation of endogenous AR target genes. Indeed, we show that truncated AR variants with nuclear as well as nuclear/cytoplasmic localization patterns can drive androgen-independent growth of PCa cells. Together, our data demonstrate that diverse truncated AR species with varying efficiencies of nuclear localization can contribute to castration-resistant PCa pathology by driving persistent ligand-independent AR transcriptional activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22532567      PMCID: PMC3366007          DOI: 10.1074/jbc.M112.352930

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  HSP40 binding is the first step in the HSP90 chaperoning pathway for the progesterone receptor.

Authors:  M Patricia Hernández; Ahmed Chadli; David O Toft
Journal:  J Biol Chem       Date:  2002-01-23       Impact factor: 5.157

2.  p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation.

Authors:  M Fu; C Wang; A T Reutens; J Wang; R H Angeletti; L Siconolfi-Baez; V Ogryzko; M L Avantaggiati; R G Pestell
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function.

Authors:  Maofu Fu; Chenguang Wang; Jian Wang; Xueping Zhang; Toshiyuki Sakamaki; Y G Yeung; Chawnshang Chang; Torsten Hopp; Suzanne A W Fuqua; Ellis Jaffray; Ron T Hay; Jorma J Palvimo; Olli A Jänne; Richard G Pestell
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

5.  Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells.

Authors:  Y de Launoit; R Veilleux; M Dufour; J Simard; F Labrie
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

6.  Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor.

Authors:  Anthony J Saporita; Qiuheng Zhang; Neema Navai; Zehra Dincer; Junghyun Hahn; Xiaoyan Cai; Zhou Wang
Journal:  J Biol Chem       Date:  2003-08-15       Impact factor: 5.157

7.  Structural basis of androgen receptor binding to selective androgen response elements.

Authors:  Paul L Shaffer; Arif Jivan; D Eric Dollins; Frank Claessens; Daniel T Gewirth
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-22       Impact factor: 11.205

8.  Colorimetric growth assay for epidermal cell cultures by their crystal violet binding capacity.

Authors:  B Bonnekoh; A Wevers; F Jugert; H Merk; G Mahrle
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

9.  AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.

Authors:  Y Li; T H Hwang; L A Oseth; A Hauge; R L Vessella; S C Schmechel; B Hirsch; K B Beckman; K A Silverstein; S M Dehm
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

10.  The common 90-kd protein component of non-transformed '8S' steroid receptors is a heat-shock protein.

Authors:  M G Catelli; N Binart; I Jung-Testas; J M Renoir; E E Baulieu; J R Feramisco; W J Welch
Journal:  EMBO J       Date:  1985-12-01       Impact factor: 11.598

View more
  119 in total

1.  Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.

Authors:  Kush Dalal; Meixia Che; Nanette S Que; Aishwariya Sharma; Rendong Yang; Nada Lallous; Hendrik Borgmann; Deniz Ozistanbullu; Ronnie Tse; Fuqiang Ban; Huifang Li; Kevin J Tam; Mani Roshan-Moniri; Eric LeBlanc; Martin E Gleave; Daniel T Gewirth; Scott M Dehm; Artem Cherkasov; Paul S Rennie
Journal:  Mol Cancer Ther       Date:  2017-08-03       Impact factor: 6.261

Review 2.  Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

Authors:  Kathryn E Ware; Mariano A Garcia-Blanco; Andrew J Armstrong; Scott M Dehm
Journal:  Endocr Relat Cancer       Date:  2014-05-23       Impact factor: 5.678

3.  N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy.

Authors:  Sarah K Martin; Carmen A Banuelos; Marianne D Sadar; Natasha Kyprianou
Journal:  Mol Oncol       Date:  2014-11-15       Impact factor: 6.603

4.  FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.

Authors:  Laura R Bohrer; Ping Liu; Jian Zhong; Yunqian Pan; James Angstman; Lucas J Brand; Scott M Dehm; Haojie Huang
Journal:  Prostate       Date:  2013-02-06       Impact factor: 4.104

5.  Role of WNT7B-induced noncanonical pathway in advanced prostate cancer.

Authors:  Dali Zheng; Keith F Decker; Tianhua Zhou; Jianquan Chen; Zongtai Qi; Kathryn Jacobs; Katherine N Weilbaecher; Eva Corey; Fanxin Long; Li Jia
Journal:  Mol Cancer Res       Date:  2013-02-05       Impact factor: 5.852

6.  Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Authors:  Maria Thadani-Mulero; Luigi Portella; Shihua Sun; Matthew Sung; Alexandre Matov; Robert L Vessella; Eva Corey; David M Nanus; Stephen R Plymate; Paraskevi Giannakakou
Journal:  Cancer Res       Date:  2014-02-20       Impact factor: 12.701

Review 7.  Constitutive activity of the androgen receptor.

Authors:  Siu Chiu Chan; Scott M Dehm
Journal:  Adv Pharmacol       Date:  2014

8.  CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.

Authors:  Huiying Sun; Sanjay N Mediwala; Adam T Szafran; Michael A Mancini; Marco Marcelli
Journal:  Horm Cancer       Date:  2016-03-08       Impact factor: 3.869

9.  Androgen receptor variant-driven prostate cancer II: advances in clinical investigation.

Authors:  Emmanuel S Antonarakis; Jun Luo; Andrew J Armstrong; Landon C Brown; Changxue Lu
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-24       Impact factor: 5.554

10.  Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.

Authors:  Dong Gui Hu; Theresa E Hickey; Connie Irvine; Dhilushi Dodampege Wijayakumara; Lu Lu; Wayne D Tilley; Luke A Selth; Peter I Mackenzie
Journal:  Horm Cancer       Date:  2014-02-26       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.